EU Panel Likes Monotherapy Cemiplimab for Two Cancers EU Panel Likes Monotherapy Cemiplimab for Two Cancers
In Europe, the Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for cemiplimab as monotherapy in lung cancer and basal cell carcinoma.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Basal Cell Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Hematology | Lung Cancer | Skin Cancer